Get the Stockscreener App
14.29
0.21%
-0.03
After Hours:
14.29
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
ARS Pharma Rolls Dice Again On NeffyWill Persistence Pay Off? - RTTNews
(SPRY) Investment Report - Stock Traders Daily
ARS Pharmaceuticals (NASDAQ:SPRY) Trading 5.4% HigherStill a Buy? - MarketBeat
Neffy Launches Free Epi Nasal Sprayer Program for U.S. Schools - Allergic Living
Equities Analysts Issue Forecasts for SPRY FY2025 Earnings - MarketBeat
What is William Blair's Estimate for SPRY FY2024 Earnings? - MarketBeat
William Blair Has Bullish Forecast for SPRY Q4 Earnings - MarketBeat
ARS Pharmaceuticals Launches neffyinSchools Program - GlobeNewswire
ARS Pharmaceuticals lays down 2025 objectives for epinephrine nasal spray - MSN
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Lessened by ARS Investment Partners LLC - MarketBeat
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools - The Manila Times
ARS Pharma Launches Free Neffy Nasal Spray Program for U.S. Schools to Combat Allergic Reactions - StockTitan
When (SPRY) Moves Investors should Listen - Stock Traders Daily
Analysts Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Target Price at $26.00 - MarketBeat
Raymond James Issues Positive Forecast for ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up on Analyst Upgrade - MarketBeat
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. - MSN
ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 7.6% After Analyst Upgrade - MarketBeat
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
ARS Pharmaceuticals shares surge on strong Q4 revenue for allergy spray - Investing.com Canada
ARS Pharmaceuticals (NASDAQ:SPRY) Price Target Raised to $27.00 at Leerink Partners - MarketBeat
ARS Pharmaceuticals Announces Preliminary Fourth Quarter - GlobeNewswire
ARS Pharmaceuticals' Neffy Nasal Spray Hits $7.1M in Sales Since Launch, Targets 80% Insurance Coverage - StockTitan
Barclays PLC Buys 73,127 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
(SPRY) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells 50,000 Shares of Stock - MarketBeat
Ars pharmaceuticals director Laura Shawver sells $555k in stock By Investing.com - Investing.com Australia
Ars pharmaceuticals director Laura Shawver sells $555k in stock - Investing.com India
ARS Pharmaceuticals files for approval of neffy in Canada, U.K. - Yahoo Finance
ARS Pharma seeks approval for epinephrine spray in Canada and UK - Yahoo Finance
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 2.8%Time to Sell? - MarketBeat
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S - The Manila Times
ARS Pharmaceuticals Files for Approval of neffy® in Canada - GlobeNewswire
ARS Pharma Expands Neffy Nasal Spray to UK & Canada, Targets 98% of Global Epinephrine Market - StockTitan
Top US Growth Companies With Insider Ownership In January 2025 - Simply Wall St
Market Sentiment Around Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Simply Wall St
Barclays PLC Raises Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 3.6%Time to Sell? - MarketBeat
Institutional owners may ignore ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) recent US$67m market cap decline as longer-term profits stay in the green - Yahoo Finance
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $24.00 Average Target Price from Brokerages - MarketBeat
State Street Corp Acquires 193,321 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Ars Pharmaceuticals' chief medical officer sells $1.17 million in stock By Investing.com - Investing.com Australia
ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Down 4% on Insider Selling - MarketBeat
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies - The Manila Times
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal - GlobeNewswire
Ars Pharmaceuticals' chief medical officer sells $1.17 million in stock - Investing.com
Ars Pharmaceuticals CEO sells $1.17 million in stock By Investing.com - Investing.com Canada
Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 100,000 Shares of Stock - MarketBeat
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):